182 related articles for article (PubMed ID: 28365531)
1. Macrophage activation syndrome: A new complication of checkpoint inhibitors.
Malissen N; Lacotte J; Du-Thanh A; Gaudy-Marqueste C; Guillot B; Grob JJ
Eur J Cancer; 2017 May; 77():88-89. PubMed ID: 28365531
[No Abstract] [Full Text] [Related]
2. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
[No Abstract] [Full Text] [Related]
3. Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome.
Mirza S; Hill E; Ludlow SP; Nanjappa S
Melanoma Res; 2017 Jun; 27(3):271-273. PubMed ID: 28146044
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.
Guerrero E; Johnson DB; Bachelot A; Lebrun-Vignes B; Moslehi JJ; Salem JE
Eur J Cancer; 2019 May; 113():10-13. PubMed ID: 30954881
[No Abstract] [Full Text] [Related]
5. Immune checkpoint therapy in proteinuric kidney disease.
Takenaka T; Kawai Y; Amano T
Eur J Cancer; 2018 May; 95():120-122. PubMed ID: 29530540
[No Abstract] [Full Text] [Related]
6. HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma.
Koksal AS; Toka B; Eminler AT; Hacibekiroglu I; Uslan MI; Parlak E
Ann Oncol; 2017 Dec; 28(12):3103-3104. PubMed ID: 28945827
[No Abstract] [Full Text] [Related]
7. Ipilimumab- and nivolumab-associated enterocolitis with florid necrotising granulomatous inflammation: a novel manifestation of 'immunomodulatory' enterocolitis.
Paton DJW; Warburton L; Chung K; Meniawy TM; Kumarasinghe MP
Pathology; 2018 Jun; 50(4):466-469. PubMed ID: 29735170
[No Abstract] [Full Text] [Related]
8. Guillain-Barré Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review.
Supakornnumporn S; Katirji B
J Clin Neuromuscul Dis; 2017 Dec; 19(2):80-83. PubMed ID: 29189553
[TBL] [Abstract][Full Text] [Related]
9. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
Postow MA; Sidlow R; Hellmann MD
N Engl J Med; 2018 Jan; 378(2):158-168. PubMed ID: 29320654
[No Abstract] [Full Text] [Related]
10. Immune checkpoint inhibitor rechallenge in patients with immune-related myositis.
Delyon J; Brunet-Possenti F; Leonard-Louis S; Arangalage D; Baudet M; Baroudjian B; Lebbe C; Hervier B;
Ann Rheum Dis; 2019 Nov; 78(11):e129. PubMed ID: 30242031
[No Abstract] [Full Text] [Related]
11. Immune checkpoint inhibitors-related orchitis.
Brunet-Possenti F; Opsomer MA; Gomez L; Ouzaid I; Descamps V
Ann Oncol; 2017 Apr; 28(4):906-907. PubMed ID: 28039179
[No Abstract] [Full Text] [Related]
12. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint Inhibitor-Associated Hypophysitis.
Chang LS; Yialamas MA
J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
[No Abstract] [Full Text] [Related]
14. Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.
Necchi A; Giardiello D; Mariani L
Eur Urol; 2017 May; 71(5):840-841. PubMed ID: 27720533
[No Abstract] [Full Text] [Related]
15. Immunotherapy-associated autoimmune hemolytic anemia.
Khan U; Ali F; Khurram MS; Zaka A; Hadid T
J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
[TBL] [Abstract][Full Text] [Related]
16. Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient.
Mandalà M; Merelli B; Indriolo A; Tondini C
Eur J Cancer; 2018 May; 95():130-132. PubMed ID: 29559189
[No Abstract] [Full Text] [Related]
17. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
Firwana B; Ravilla R; Raval M; Hutchins L; Mahmoud F
J Oncol Pharm Pract; 2017 Dec; 23(8):620-624. PubMed ID: 27590328
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid lymphocytosis: a hallmark of neurological complications during checkpoint inhibition.
Tonk EHJ; Snijders TJ; Koldenhof JJ; van Lindert ASR; Suijkerbuijk KPM
Eur J Cancer; 2019 Nov; 121():1-3. PubMed ID: 31522128
[No Abstract] [Full Text] [Related]
19. Hypophysitis on immunotherapy with checkpoint inhibitors.
Jäger IM; Kohlmann J; Simon JC; Sandner B; Tönjes A; Ziemer M
J Dtsch Dermatol Ges; 2019 Nov; 17(11):1168-1170. PubMed ID: 31701648
[No Abstract] [Full Text] [Related]
20. Check point inhibitors a new era in renal cell carcinoma treatment.
Alsharedi M; Katz H
Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
